Megamergers are 'good for pharma'
This article was originally published in Scrip
Executive Summary
In the wake of news that Actavis plans to buy Forest Laboratories for $25bn (scripintelligence.com, 20 February 2014), McKinsey & Co has published a report explaining why the pharmaceutical megamerger is so attractive within the industry.